Launch of the digital clinical decision support tool OptiCor™

Over the past two years, we have been developing the OptiCor™ platform for tenacio, a German medical startup. This innovative platform enables physicians to make informed and personalized treatment decisions based on study data for patients with atrial fibrillation. Having been reviewed by the U.S. Food and Drug Administration (FDA), OptiCor™ is now commercially available in the United States. Through the use of various parameters drawn from patients' medical records, OptiCor™ can accurately calculate the individual likelihood of bleeding, strokes, and mortality, empowering physicians to tailor treatment plans to each patient's unique needs. Additionally, the platform offers sophisticated modeling capabilities, providing insights into how different treatment options may impact the progression of the disease. We are thrilled to further enhance the OptiCor™ platform and continue collaborating with tenacio in the fight against cardiovascular diseases, the leading cause of death worldwide.